A Trial of Lopinavir-Ritonavir in Covid-19. Reply.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

19 citing papers in PubMed.

1. Repurposing clinically available drugs and therapies for pathogenic targets to combat SARS-CoV-2.MedComm · 2023
   Review
2. The Adverse Reactions of Lianhua Qingwen Capsule/Granule Compared With Conventional Drug in Clinical Application: A Meta-Analysis.Frontiers in pharmacology · 2022
   Review
3. Chronic Administration of COVID-19 Drugs Fluvoxamine and Lopinavir Shortens Action Potential Duration by Inhibiting the Human Ether-à-go-go-Related Gene and Cav1.2.Frontiers in pharmacology · 2022
   Article
4. Repurposing of FDA Approved Drugs Against SARS-CoV-2 Papain-Like Protease: Computational, Biochemical, andFrontiers in microbiology · 2022
   Article
5. Repurposing existing drugs: identification of SARS-CoV-2 3C-like protease inhibitors.Journal of enzyme inhibition and medicinal chemistry · 2021
   Article
6. Chest Computed Tomography (CT) as a Predictor of Clinical Course in Coronavirus Disease.Medical science monitor : international medical journal of experimental and clinical research · 2021
   Article
7. Dynamics, behaviours, and anomaly persistence in cryptocurrencies and equities surrounding COVID-19.Physica A · 2021
   Article
8. SARS-CoV-2: Targeted managements and vaccine development.Cytokine & growth factor reviews · 2021
   Review
9. Changes to the extreme and erratic behaviour of cryptocurrencies during COVID-19.Physica A · 2021
   Article
10. Association between COVID-19 cases and international equity indices.Physica D. Nonlinear phenomena · 2021
    Article
11. Confronting the threat of SARS-CoV-2: Realities, challenges and therapeutic strategies (Review).Experimental and therapeutic medicine · 2021
    Review
12. FDA approved drugs with pharmacotherapeutic potential for SARS-CoV-2 (COVID-19) therapy.Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy · 2020
    Review
13. The Course of Mild and Moderate COVID-19 Infections-The Unexpected Long-Lasting Challenge.Open forum infectious diseases · 2020
    Article
14. Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2020
    Observational
15. Efficacy and safety of Lianhua Qingwen combined with conventional antiviral Western Medicine in the treatment of coronavirus disease (covid-19) in 2019: Protocol for a systematic review and meta-analysis.Medicine · 2020
    Article
16. Role of Lopinavir/Ritonavir in the Treatment of Covid-19: A Review of Current Evidence, Guideline Recommendations, and Perspectives.Journal of clinical medicine · 2020
    Review
17. Antiviral Agent Therapy Optimization in Special Populations of COVID-19 Patients.Drug design, development and therapy · 2020
    Review
18. Update on Antiviral Strategies Against COVID-19: Unmet Needs and Prospects.Frontiers in immunology · 2020
    Review
19. COVID-19: High-JAKing of the Inflammatory "Flight" by Ruxolitinib to Avoid the Cytokine Storm.Frontiers in oncology · 2020
    Article

Corrections and comments

• Comment on
  A Trial of Lopinavir-Ritonavir in Covid-19.2020
• Comment on
  A Trial of Lopinavir-Ritonavir in Covid-19.2020
• Comment on
  A Trial of Lopinavir-Ritonavir in Covid-19.2020
• Comment on
  A Trial of Lopinavir-Ritonavir in Covid-19.2020
• Comment on
  A Trial of Lopinavir-Ritonavir in Covid-19.2020

Authors and funding

3 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as